

Discussions with leaders: Henryk Barthel talks with Julie Price about her career in advancing neuroimaging to enhance understanding of the brain and neurodegeneration. **Page 499**

Theranostics and SBRT in oligometastasis: Kishan and colleagues address the current promise and potential contributions of metastasis-directed therapy in oligometastatic prostate cancer, including radiopharmaceutical and stereotactic body radiation therapies in managing disease. . . . **Page 502**

¹⁸F-FDG MTV in lymphoma: Barrington and colleagues look at current evidence and promising datasets supporting the use of PET-derived metabolic tumor volume for clinical risk stratification in lymphoma. **Page 510**

⁶⁸Ga-FAPI in invasive lobular cancer: Sahin and colleagues assess the utility of ⁶⁸Ga-fibroblast activation protein inhibitor PET/CT as an alternative to ¹⁸F-FDG PET/CT for staging invasive lobular breast cancer. **Page 512**

Early radiation pneumonitis model for NSCLC: Thor and colleagues explore whether published models and pretreatment ¹⁸F-FDG PET/CT-derived features can predict radiation pneumonitis within 3 mo after completion of chemoradiation/immunotherapy in stage III non-small cell lung cancer. **Page 520**

NSCLC diagnosis and FAP expression: Li and colleagues report on the diagnostic accuracy of ⁶⁸Ga-labeled fibroblast activation protein inhibitor-04 PET/CT for lymph node metastases in non-small cell lung cancer and identify tumor ⁶⁸Ga-FAPI-04 uptake correlations with FAP expression. **Page 527**

[⁶⁷Cu]Cu-EB-TATE theranostic and NETs: Njotu and colleagues detail preclinical evaluation of this long-lived somatostatin analog against somatostatin receptor subtype 2-positive neuroendocrine tumors. **Page 533**

PSMA PET AUC updates: Hope and Jadvar review current indications for the use of PSMA PET imaging and note additional appropriate use criteria occasioned by the approval of ¹⁸F-rh-PSMA-7.3. **Page 540**

Pretreatment PSMA PET/CT and ²²³Ra outcomes: Bosch and colleagues compare outcomes in patients with bone-only metastatic castration-resistant prostate cancer selected for ²²³Ra-dichloride therapy by baseline imaging with PSMA PET/CT or CT. **Page 541**

SUV_{max} on PSMA PET and γ -probe signal: Berrens and colleagues study correlations between the SUV_{max} of recurrent prostate cancer lesions on preoperative PSMA PET/CT and their intraoperative counts measured using the Drop-In γ -probe. **Page 548**

⁶⁸Ga-PSMA PET/MRI and PI-RADS 3 classification: Shi and colleagues explore the added value of ⁶⁸Ga-labeled PSMA-11 PET/MRI in classifying Prostate Imaging Reporting and Data System category 3 lesions to avoid unnecessary biopsies. **Page 555**

RECIP 1.0 and [¹⁸F]PSMA-1007 PET: Hartrampf and colleagues evaluate the performance of these recently proposed response criteria in predicting overall survival in patients undergoing PSMA-targeted radioligand therapy and imaged with [¹⁸F]PSMA-1007 PET/CT. **Page 560**

STP with NLME and model selection: Hardiansyah and colleagues investigate the accuracy of single-time-point renal dosimetry imaging using SPECT/CT data, a nonlinear mixed-effects model, and a population-based model selection for ¹⁷⁷Lu-labeled PSMA therapy. **Page 566**

[¹⁷⁷Lu]Lu-DOTA-JR11 and treatment-resistant meningioma: Eigler and colleagues compare the therapeutic index of this new radiolabeled somatostatin receptor antagonist with that of the established receptor agonist [¹⁷⁷Lu]Lu-DOTA-TOC in progressive, standard therapy-refractory meningioma. **Page 573**

Theranostic potential in ovarian cancer: Mack and colleagues research the preclinical theranostic promise of a radiolabeled humanized antibody, huAR9.6, in targeting fully glycosylated and hypoglycosylated MUC16 isoforms in ovarian cancer. **Page 580**

GPC-3 targeting in liver cancer: Lin and colleagues detail preclinical studies demonstrating the potential of a novel compound containing a macrocyclic peptide binder that can be complexed with different radioisotopes as a theranostic agent for GPC3-positive hepatocellular carcinoma. **Page 586**

PSMA-targeted α -radiotherapy: El Fakiri and colleagues report on the design, development, and preclinical evaluation of ²¹¹At-based radiopharmaceuticals that use clinically approved PSMA-617 as part of a theranostic strategy in prostate cancer. **Page 593**

Internal carotids for PET quantification: Providência and colleagues assess the use of the internal carotids for quantifying brain glucose metabolism before and after partial-volume correction in ¹⁸F-FDG PET imaging. **Page 600**

Total-body PET/CT applications: Slart and members of the SNMMI Cardiovascular Council provide perspective on potential applications, challenges, opportunities, and remaining challenges of applying PET/CT with a long-axial field of view in cardiovascular disease. **Page 607**

PET/CT and angiogenesis in ILD: Porter and colleagues investigate correlations between [¹⁸F]FDG uptake and lung biopsy histologic markers in patients with fibrotic interstitial lung disease, highlighting the potential role of vasculature and angiogenesis in fibrosis. **Page 617**

Automated PET/CT H&N tumor delineation: Kovacs and colleagues identify and evaluate promising state-of-the-art deep learning methods for ¹⁸F-FDG PET gross tumor volume delineation in head and neck cancer. **Page 623**

Mutations, RT, and NSCLC: Bourbonne introduce a model enabling prediction of KEAP1/NFE2L2 mutational status using PET/CT-extracted radiomics features to classify patients with non-small cell lung cancer at risk of local relapse after radiotherapy. **Page 630**

NSCLC PET biomarkers: Hovhannisyan-Baghdasarian and colleagues assess imaging parameters characterizing the shift of SUV_{max} toward the lesion edge during tumor progression, their complementarity to conventional PET features, and prognostic value in advanced non-small cell lung cancer. **Page 635**

Automated PET/CT tumor quantification: Leung and colleagues report on development of a deep semisupervised transfer learning approach for fully automated, whole-body tumor segmentation and prognosis on PET/CT. **Page 643**

uMI Panorama PET/CT: Li and colleagues provide an assessment of the physical performance of this novel PET/CT system using silicon photomultiplier and application-specific integrated circuit technologies, per the National Electrical Manufacturers Association NU 2-2018 standard. **Page 652**

Accomplishments of Saul Hertz: Greenspan and colleagues review the professional milestones of this nuclear medical pioneer in radioactive iodine therapy, including personal and historical context relevant to his legacy in the field. **Page 659**

²¹²Pb SPECT/CT in pCa: Griffiths and colleagues present first-in-humans ²¹²Pb SPECT/CT images in a 73-year-old man with metastatic castration-resistant prostate cancer, highlighting potential for postinfusion radiopharmaceutical biodistribution imaging and patient-specific dosimetry for ²¹²Pb-targeted α -therapy. **Page 664**

¹²³I-PARPi in neuroendocrine carcinoma: Ndlovu and colleagues describe [¹²³I]-PARP-inhibitor SPECT/CT as a noninvasive tool for whole-body assessment of PARP upregulation in lung small-cell neuroendocrine carcinoma, with implications for patient selection and response prediction in PARPi therapy. **Page 665**